MedTrace Logo

Pharmacokinetics of Topical SB204 in Adolescents With Acne Vulgaris

NCT02801903 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2018-10-12

No results posted yet for this study

Summary

A Phase 1, Single-center, Open-label, Pharmacokinetic, Safety and Tolerability Study of SB204 in Adolescents with Moderate to Severe Acne Vulgaris

Conditions

  • Acne Vulgaris

Interventions

DRUG

SB204 4%

Topically Once Daily (AM)

Sponsors & Collaborators

  • WCCT Global

    collaborator INDUSTRY

  • Novan, Inc.

    lead INDUSTRY

Principal Investigators

  • M. Joyce Rico, MD · Novan, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-07
Primary Completion
2016-08-31
Completion
2016-08-25

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02801903 on ClinicalTrials.gov